These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 14561112)

  • 1. The effect of human immunodeficiency virus-1 protease inhibitors on the toxicity of a variety of cells.
    Germinario RJ; Colby-Germinario SP
    In Vitro Cell Dev Biol Anim; 2003; 39(7):275-9. PubMed ID: 14561112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral protease inhibitors prevent l6 muscle cell fusion by reducing calpain activity.
    Colby-Germinario SP; Chalifour LE; Antonecchia A; Germinario RJ
    AIDS Res Hum Retroviruses; 2004 Oct; 20(10):1057-62. PubMed ID: 15585096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries.
    Chai H; Yang H; Yan S; Li M; Lin PH; Lumsden AB; Yao Q; Chen C
    J Acquir Immune Defic Syndr; 2005 Sep; 40(1):12-9. PubMed ID: 16123675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary fat alters HIV protease inhibitor-induced metabolic changes in mice.
    Lenhard JM; Croom DK; Weiel JE; Spaltenstein A; Reynolds DJ; Furfine ES
    J Nutr; 2000 Sep; 130(9):2361-6. PubMed ID: 10958836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro.
    Jones K; Hoggard PG; Khoo S; Maher B; Back DJ
    Br J Clin Pharmacol; 2001 Jan; 51(1):99-102. PubMed ID: 11167671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
    Gao W; Kishida T; Kageyama M; Kimura K; Yoshikawa Y; Shibata N; Takada K
    Antivir Chem Chemother; 2002 Jan; 13(1):17-26. PubMed ID: 12180646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.
    Vernochet C; Azoulay S; Duval D; Guedj R; Ailhaud G; Dani C
    AIDS; 2003 Oct; 17(15):2177-80. PubMed ID: 14523274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.
    Dragsted UB; Gerstoft J; Pedersen C; Peters B; Duran A; Obel N; Castagna A; Cahn P; Clumeck N; Bruun JN; Benetucci J; Hill A; Cassetti I; Vernazza P; Youle M; Fox Z; Lundgren JD;
    J Infect Dis; 2003 Sep; 188(5):635-42. PubMed ID: 12934178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Marcelin AG; Dalban C; Peytavin G; Lamotte C; Agher R; Delaugerre C; Wirden M; Conan F; Dantin S; Katlama C; Costagliola D; Calvez V
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4687-92. PubMed ID: 15561845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations.
    Lepsík M; Kríz Z; Havlas Z
    Proteins; 2004 Nov; 57(2):279-93. PubMed ID: 15340915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.
    Holguín A; Paxinos E; Hertogs K; Womac C; Soriano V
    J Clin Virol; 2004 Nov; 31(3):215-20. PubMed ID: 15465415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 isolates.
    Tremblay C; Merrill DP; Chou TC; Hirsch MS
    J Acquir Immune Defic Syndr; 1999 Dec; 22(5):430-6. PubMed ID: 10961603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats.
    Shibata N; Kageyama M; Kishida T; Kimura K; Yoshikawa Y; Kuwahara T; Toh J; Shirasaka T; Takada K
    Biopharm Drug Dispos; 2003 Nov; 24(8):335-44. PubMed ID: 14595702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
    Paulsen D; Liao Q; Fusco G; St Clair M; Shaefer M; Ross L
    AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1011-9. PubMed ID: 12396453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals.
    Morse GD; Rosenkranz S; Para MF; Segal Y; Difrancesco R; Adams E; Brizz B; Yarasheski KE; Reichman RC
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3373-81. PubMed ID: 16048950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The danish protease inhibitor study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection.
    Katzenstein TL; Kirk O; Pedersen C; Lundgren JD; Nielsen H; Obel N; Nielsen C; Mathiesen LR; Gerstoft J
    J Infect Dis; 2000 Sep; 182(3):744-50. PubMed ID: 10950767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors.
    Gruber A; Berlit J; Speth C; Lass-Flörl C; Kofler G; Nagl M; Borg-von Zepelin M; Dierich MP; Würzner R
    Immunobiology; 1999 Sep; 201(1):133-44. PubMed ID: 10532286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
    Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
    HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors.
    Dulioust A; Paulous S; Guillemot L; Delavalle AM; Boué F; Clavel F
    J Virol; 1999 Jan; 73(1):850-4. PubMed ID: 9847401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.